Vesugen
Also known as: Lys-Glu-Asp · KED
A Khavinson vascular short peptide (Lys-Glu-Asp) targeting vascular-endothelial gene expression, with cerebrovascular research relevance in cognitive-ageing and stroke-recovery contexts.
Vesugen (Lys-Glu-Asp) is a Khavinson vascular short peptide targeting vascular-endothelial function, with cerebrovascular-cognition research relevance.
Evidence tier: B — clinical evidence (trials or approved use in some jurisdictions)
- Category
- Neuroprotection
- Half-life
- Short plasma half-life; sustained transcriptional effects extend beyond exposure
Section 1
Overview
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator programme at the St. Petersburg Institute of Bioregulation and Gerontology. It is positioned within the Khavinson framework as a vascular-endothelial-targeted bioregulator — a short peptide proposed to modulate transcription in vascular endothelial cells via the direct DNA-binding mechanism that characterises the whole Khavinson short-peptide approach.
The peptide's relevance to cognitive research on this reference is via the vascular-cognition link: cerebrovascular dysfunction is a substantial contributor to age-related cognitive decline, and interventions that support vascular endothelial function have a plausible cognitive-relevance angle. Vesugen has been characterised in Russian preclinical and clinical research for effects on vascular endothelial function, angiogenic capacity, and vascular-related cognitive endpoints in aged cohorts.
The published evidence base is smaller and less internationally-replicated than for Pinealon or Epitalon. Independent Western replication of the distinctive Khavinson-school mechanistic claims is limited across the whole family; Vesugen sits at the thinner end of that spectrum.
Section 2
Discovery & History
- Developed at the St. Petersburg Institute of Bioregulation and Gerontology as the vascular arm of the Khavinson short-peptide programme, alongside Pinealon (pineal-directed), Epitalon (pineal / gerontoprotective), and the other tissue-directed bioregulators.
- Studied in Russian preclinical and clinical research for effects on vascular endothelial cell function, angiogenic capacity, and cerebrovascular endpoints.
- Used in Russian clinical practice as part of cyclical bioregulator protocols for cardiovascular and cerebrovascular indications.
- Not approved as a medicine in Western jurisdictions; remains a research chemical in the UK.
- Independent Western clinical evaluation of the compound is not documented.
Section 3
Mechanism of Action
- 1Proposed direct binding to promoter regions of vascular-endothelial-cell-relevant genes — the central Khavinson-school mechanism, applied specifically to vascular tissue targets.
- 2Upregulation of endothelial nitric oxide synthase (eNOS) expression and downstream NO signalling in vascular endothelial cell preparations — the biochemical footprint of the vascular-targeting claim, and the mechanistic root for the observed vasodilatory and antihypertensive-adjacent effects.
- 3Reported effects on vascular endothelial growth factor (VEGF) expression, contributing to angiogenic and vascular-repair effects in the injury-recovery research applications and providing mechanistic overlap with the broader angiogenic peptide research programme.
- 4Anti-atherogenic effects reported in some animal and cell-culture work — reductions in oxidised-LDL uptake by macrophages and preserved endothelial barrier function under hyperlipidaemic challenge.
- 5Cerebrovascular effects — reported improvements in cerebral perfusion parameters, reduced cerebral small-vessel-disease markers, and vascular-cognitive endpoints in aged animal models and Russian elderly-population research.
- 6Antioxidant effects at the vascular endothelium — upregulation of endothelial superoxide dismutase (SOD3) expression and reduced endothelial ROS accumulation under oxidative-stress challenge, extending the antioxidant activity common to the Khavinson family into vascular tissue specifically.
- 7Modulation of endothelin-1 expression and vascular-tone-regulating factor balance, contributing to the reported blood-pressure-normalising effects in Russian clinical experience.
- 8Anti-thrombogenic effects via modulation of vascular endothelial cell surface-expression profile — reduced platelet adhesion and altered coagulation-factor expression in some experimental models.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Cerebrovascular support relevant to age-related cognitive decline and cerebrovascular-cognitive-impairment research — the primary cognitive-relevance angle for the compound.
- 2Reported effects on vascular endothelial function and angiogenic capacity in preclinical models, with measurable improvements in flow-mediated dilation and endothelial-progenitor-cell mobilisation.
- 3Anti-atherogenic angle providing a cardiovascular-adjacent research application, complementary to but distinct from the primary cerebrovascular positioning.
- 4Part of the broader Khavinson gerontoprotective bioregulator programme, with combined-compound synergies in the standard multi-bioregulator protocol.
- 5Well-tolerated in the reported Russian clinical experience across paediatric, adult, and elderly populations.
- 6Reported effects on markers of vascular ageing (arterial stiffness by pulse-wave-velocity measurement, endothelial dysfunction markers, VCAM/ICAM expression) in some clinical work.
- 7Blood-pressure-normalising effects in hypertensive research subjects, mediated through the endothelial NO-eNOS mechanism rather than through direct cardiovascular receptor pharmacology.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Intranasal / parenteral (research) | Microgram-range doses in animal and clinical-research protocols | Cyclical (10–20 day courses) following the standard Khavinson pattern | Short courses repeated every 4–6 months rather than continuous administration |
Note: No standardised Western clinical protocol exists; sourcing quality is highly variable given the Khavinson-family supply landscape.
Section 6
Administration Routes
- Intranasal administration — a common route in Russian bioregulator practice, exploiting nose-to-brain delivery for the cerebrovascular research angle.
- Subcutaneous and intramuscular administration in animal research and some Russian clinical protocols where systemic vascular exposure is prioritised.
- Intravenous administration in some acute cerebrovascular research contexts where rapid onset is prioritised over sustained exposure.
- Oral administration is not viable — the tripeptide is efficiently degraded by gastrointestinal proteases and undergoes near-complete first-pass metabolism.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in the reported Russian research at studied doses — consistent with the Khavinson-family unusually clean acute-tolerability profile characterised across the whole short-peptide programme.
- · Mild local irritation possible with intranasal administration; typically transient and self-limiting within the first 2–3 doses of a course.
- · Occasional mild headache during initial dosing, generally resolving with continued administration as the tolerance-adaptation curve completes.
- · Well-tolerated across paediatric, adult, and elderly research cohorts in the Russian evidence base with adverse-event rates comparable to placebo in the reported protocols.
Rare / theoretical
- · Long-term safety data outside the Khavinson group is very sparse for Vesugen specifically; chronic-use safety beyond the standard 10-day-course-per-6-months protocol is not well-characterised.
- · The proposed transcriptional mechanism remains debated in Western pharmacology and would require independent replication to inform a full regulatory-scale safety evaluation.
- · Theoretical interaction with anti-angiogenic pharmaceuticals (bevacizumab, aflibercept) given the VEGF-related mechanistic angle, though no documented clinical events exist.
- · Rare hypersensitivity reactions — theoretical concern based on peptide chemistry rather than documented clinical experience.
Contraindications
- · Not licensed for human use in the UK — supply for human consumption is prohibited under the Human Medicines Regulations 2012.
- · Pregnancy and lactation — no controlled human data.
- · Active malignancy with angiogenic-driven pathology — theoretical contraindication via the VEGF-related mechanism.
Section 8
UK & EU Regulatory Context
United Kingdom
Not a licensed medicine in the UK. Research chemical only.
European Union
Not approved by the EMA. Used in Russian research and clinical practice.
Section 9
Clinical Studies Summary
Vesugen effects on vascular endothelial function
Khavinson-group preclinical research demonstrating effects of Vesugen on vascular endothelial cell function in cellular preparations, including measurable eNOS expression upregulation, endothelial-cell migration in wound-healing assays, and angiogenic-capacity endpoints via tube-formation experiments. The biochemical scaffold for the vascular-targeting positioning and the mechanistic entry point for the broader vascular research programme on the compound.
Vesugen in cerebrovascular ageing research
Russian preclinical research in aged Wistar rat and mouse models reporting improvements in cerebral perfusion parameters (measured by laser Doppler flowmetry), reduced cerebral small-vessel-disease histological markers, and vascular-cognitive endpoints following cyclical Vesugen administration versus vehicle controls, extending the vascular-mechanism into the cerebrovascular-cognitive research context.
Vesugen in the Khavinson bioregulator gerontoprotective framework
Cohort-level Russian gerontology work covering multiple Khavinson bioregulators including Vesugen in the standard cyclical multi-bioregulator protocol, reporting reductions in vascular-cause morbidity (stroke, myocardial infarction, vascular dementia) and mortality across long-term follow-up in elderly cohorts. The compound is one component of the broader gerontoprotective protocol rather than the sole intervention, but the multi-bioregulator programme's positive outcomes are attributed partly to Vesugen's vascular arm.
Vesugen anti-atherogenic mechanism characterisation
Molecular-pharmacology study characterising Vesugen's effects on macrophage oxidised-LDL uptake, endothelial-barrier preservation under hyperlipidaemic challenge, and vascular smooth muscle cell proliferation markers. Provides the mechanistic scaffold for the anti-atherogenic angle of the compound's positioning and extends the vascular-mechanism framework beyond direct endothelial-cell effects.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing Vesugen for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Vesugen from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.